Canagliflozin (TA-7284)

DRUG3 trials

Sponsors

Tanabe Pharma Corporation

Conditions

Type 2 Diabetes Mellitus

Phase 4

Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

CompletedNCT02220920

Tanabe Pharma CorporationType 2 Diabetes Mellitus

Start: 2014-08-31End: 2015-07-31Updated: 2026-01-08

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus

CompletedNCT02227849

Tanabe Pharma CorporationType 2 Diabetes Mellitus

Start: 2014-08-31End: 2016-03-31Updated: 2026-01-08

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

CompletedNCT02622113

Tanabe Pharma CorporationType 2 Diabetes Mellitus

Start: 2014-12-31End: 2016-04-30Updated: 2026-01-08

Related Papers

Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.

2016-06-1861 citations